Mallinckrodt to Buy Ocera Therapeutics

Nov 06, 2017

Mallinckrodt has announced that it has entered into an agreement to purchase Ocera Therapeutics, a California-based biopharma company focused on developing treatments for liver-related diseases.

Mallinckrodt, a specialty pharma manufacturer headquartered in the UK, has agreed to purchase Ocera for $1.52 per share, or about $42 million, plus additional cash payments of up to $75 million.

Of particular interest to Mallinckrodt is Ocera's developmental product OCR-002, an ammonia scavenger that is being studied for treatment of hepatic encephalopathy — a loss of brain function when the liver fails to filter out toxins from the blood — that occurs as a complication of acute or chronic liver disease.

Read the press release
l

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments